TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06269601

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Upper Limb Rotation Test
Description: The athletes were instructed to perform a 90° abduction and 90° external rotation of the shoulder, accompanied by trunk rotation for a duration of 15 seconds. The number of repetitions was recorded. The tested side was the upper extremity in which the closed kinetic chain position was maintained. The test was repeated three times, and the average of the results was calculated.
Study: NCT05229354

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TV005
Description: The TV005 admixture is comprised of four monovalent dengue vaccine candidates representing each of the four DENV serotypes: rDEN1Δ30, rDEN2/4Δ30(ME), rDEN3Δ30/31, and rDEN4Δ30.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rDEN2Δ30-7169 attenuated virus strain
Description: based on a cDNA derived DENV-2 virus (strain Tonga/74) in which the 3´ UTR of DENV-2 contains a 30 (nt) deletion (nt 173 - 143) homologous to the ∆30 deletion in the 3´ UTR of rDEN4Δ30 (named Δ30 for consistency). A plasmid was constructed to encode the entire genome of DENV-2 Tonga/74. The cDNA of the 3´ UTR of DENV-2 Tonga/74 was then modified to introduce a 31-nucleotide deletion homologous to the DEN4Δ30 deletion (∆30). Genome-length, capped, RNA transcripts were synthesized from the plasmid p2Δ30-7169 and purified

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rDEN2Δ30-7169 attenuated virus strain
Description: based on a cDNA derived DENV-2 virus (strain Tonga/74) in which the 3´ UTR of DENV-2 contains a 30 (nt) deletion (nt 173 - 143) homologous to the ∆30 deletion in the 3´ UTR of rDEN4Δ30 (named Δ30 for consistency). A plasmid was constructed to encode the entire genome of DENV-2 Tonga/74. The cDNA of the 3´ UTR of DENV-2 Tonga/74 was then modified to introduce a 31-nucleotide deletion homologous to the DEN4Δ30 deletion (∆30). Genome-length, capped, RNA transcripts were synthesized from the plasmid p2Δ30-7169 and purified
Study: NCT05101161

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurofeedback
Description: Modulating brain oscillations based on visual neurofeedback
Study: NCT05898334

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Biophoton Generators
Description: The whole body, including brain, of the study participant will be sleeping inside of the strong biophoton field so her/his entire body will be energized to promote self-healing.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Inactive Biophoton Generators
Description: The whole body, including brain, of the study participant will be sleeping inside of the normal hotel bed and the participant will not receive any biophotons.
Study: NCT05373680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Patients will receive metformin 1000 mg PO daily added to their usual therapy for the management of CKD (including the management of predisposing causes with other supportive care).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: Patients will receive empagliflozin 10 mg daily PO added to their usual therapy for the management of CKD (including the management of predisposing causes with other supportive care).

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Patients will receive their usual therapy for the management of CKD (including the management of predisposing causes with other supportive care).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Patients will receive their usual therapy for the management of CKD (including the management of predisposing causes with other supportive care).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Patients will receive their usual therapy for the management of CKD (including the management of predisposing causes with other supportive care).
Study: NCT05202977

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SinocrownTM Transcatheter Aortic Valve Replacement System
Description: Subjects receiving SinocrownTM Transcatheter Aortic Valve Replacement System of Lepu Medical
Study: NCT05409976

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GORE® VIAFORT Vascular Stent
Description: Treatment of symptomatic IVC obstruction with or without combined iliofemoral obstruction with the GORE® VIAFORT Vascular Stent.
Study: NCT05476549

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lemon verbena
Description: Lemon verbena supplement administered at an estimated daily dose of 15mg/kg

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo supplement containing carrier material only
Study: NCT01784510

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: distance of dissection of gastrocolic ligament from pylorus

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: distance of dissection of gastrocolic ligament from pylorus
Study: NCT06719609

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard lace-up ankle brace
Description: The influence of lace-up ankle brace on gait biomechanics

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard lace-up ankle brace
Description: The influence of lace-up ankle brace on gait biomechanics
Study: NCT06082817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Testosterone Undecanoate
Description: 50mg oral testosterone undecanoate daily
Study: NCT06687889

Intervention type: OTHER
Intervention: Timed Up and Go Test
Description: Timed Up and Go Test

Intervention type: OTHER
Intervention: Timed Up and Go Test
Description: Timed Up and Go Test
Study: NCT06629259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guanfacine Extended Release (XR)
Description: 3mg tablet once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo tablet once daily
Study: NCT05967416

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SIRPant-M
Description: Autologous activated macrophage cell therapy manufactured from peripheral blood mononuclear cells given by intratumoral injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SIRPant-M
Description: Autologous activated macrophage cell therapy manufactured from peripheral blood mononuclear cells given by intratumoral injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SIRPant-M
Description: Autologous activated macrophage cell therapy manufactured from peripheral blood mononuclear cells given by intratumoral injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SIRPant-M
Description: Autologous activated macrophage cell therapy manufactured from peripheral blood mononuclear cells given by intratumoral injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SIRPant-M
Description: Autologous activated macrophage cell therapy manufactured from peripheral blood mononuclear cells given by intratumoral injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SIRPant-M
Description: Autologous activated macrophage cell therapy manufactured from peripheral blood mononuclear cells given by intratumoral injection

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External-beam radiotherapy (XRT)
Description: Radiotherapy given by external beam to the IT-injected lesion only

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External-beam radiotherapy (XRT)
Description: Radiotherapy given by external beam to the IT-injected lesion only

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External-beam radiotherapy (XRT)
Description: Radiotherapy given by external beam to the IT-injected lesion only

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External-beam radiotherapy (XRT)
Description: Radiotherapy given by external beam to the IT-injected lesion only
Study: NCT06745570

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Modification and Sleep Intervention
Description: This study is being performed to develop, refine, and test the effects of a group lifestyle modification intervention augmented with a sleep intervention on weight loss, eating behaviors, and sleep outcomes. Results from this study will inform future studies to test the efficacy of this intervention. This intervention is being offered as part of a research study within Drexel University's WELL Center. Participants will receive remote, group-based, weekly weight loss and sleep coaching (90 minutes per coaching session) for 16 weeks.
Study: NCT04892147

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobility-Oriented Behavioral Activation
Description: 12-weeks of mobility-oriented behavioral activation group
Study: NCT06719609

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard high ankle-sprain (HAS) brace
Description: The influence of standard HAS brace on gait biomechanics
Study: NCT04892147

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mobility-Oriented Behavioral Activation
Description: 12-weeks of mobility-oriented behavioral activation group
Study: NCT04745234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mogamulizumab
Description: For the first 28-day induction cycle (C1), mogamulizumab 1 mg/kg will be administered as an IV infusion through a 0.22- or 0.2-μm in-line filter over at least 60 minutes on Days 1, 8, 15, and 22.~For all subsequent 28-day cycles (C2, 3, 4, etc.), mogamulizumab 2 mg/kg will be administered as an IV infusion over at least 60 minutes on Day 1 of each subsequent therapy cycle.
Study: NCT06719609

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard high ankle-sprain (HAS) brace
Description: The influence of standard HAS brace on gait biomechanics

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-profile HAS brace
Description: The influence of low-profile HAS brace on gait biomechanics

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-profile HAS brace
Description: The influence of low-profile HAS brace on gait biomechanics

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No ankle brace or tape
Description: The influence of no ankle tape or brace on gait biomechanics

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No ankle brace or tape
Description: The influence of no ankle tape or brace on gait biomechanics
Study: NCT06722235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mezagitamab
Description: Mezagitamab injection administered SC.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Mezagitamab placebo-matching injection administered SC.
Study: NCT06729762

Intervention type: PROCEDURE
Intervention: ultrasound-guided thermal ablation
Description: radiofrequency ablation, microwave ablation, laser ablation
Study: NCT06736587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP212525 10mg
Description: DWP212525 10mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP212525 30mg
Description: DWP212525 30mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP212525 30mg
Description: DWP212525 30mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP212525 50mg
Description: DWP212525 50mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP212525 50mg
Description: DWP212525 50mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP212525 100mg
Description: DWP212525 100mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP212525 100mg
Description: DWP212525 100mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP212525 200mg
Description: DWP212525 200mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP212525 200mg
Description: DWP212525 200mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP212525 400mg
Description: DWP212525 400mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP212525 placebo
Description: DWP212525 placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP212525 placebo
Description: DWP212525 placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP212525 placebo
Description: DWP212525 placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP212525 placebo
Description: DWP212525 placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP212525 placebo
Description: DWP212525 placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP212525 placebo
Description: DWP212525 placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP212525 placebo
Description: DWP212525 placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP212525 placebo
Description: DWP212525 placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP212525 placebo
Description: DWP212525 placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP212525 placebo
Description: DWP212525 placebo
Study: NCT06740500

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: probiotic sachet mainly contains Bifidobacterium animalis subsp. lactis Bi66 and maltodextrin.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin
Study: NCT06742437

Intervention type: DEVICE
Intervention: Standard sperm preparation
Description: Sperm samples in the control group will undergo traditional processing

Intervention type: DEVICE
Intervention: Standard sperm preparation
Description: Sperm samples in the control group will undergo traditional processing

Intervention type: DEVICE
Intervention: Standard sperm preparation
Description: Sperm samples in the control group will undergo traditional processing

Intervention type: DEVICE
Intervention: Standard sperm preparation
Description: Sperm samples in the control group will undergo traditional processing

Intervention type: DEVICE
Intervention: Standard sperm preparation
Description: Sperm samples in the control group will undergo traditional processing

Intervention type: DEVICE
Intervention: HyperSperm
Description: Sperm samples in the experimental group will undergo product-specific processing

Intervention type: DEVICE
Intervention: HyperSperm
Description: Sperm samples in the experimental group will undergo product-specific processing

Intervention type: DEVICE
Intervention: HyperSperm
Description: Sperm samples in the experimental group will undergo product-specific processing

Intervention type: DEVICE
Intervention: HyperSperm
Description: Sperm samples in the experimental group will undergo product-specific processing

Intervention type: DEVICE
Intervention: HyperSperm
Description: Sperm samples in the experimental group will undergo product-specific processing
Study: NCT06738576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: allogeneic mesenchymal stem cells
Description: Cell implantation is carried out in the following steps:~1. - Patient anesthesia~2. - Identification of the external urinary sphincter and the incompetent area responsible for incontinence through intraurethral cystoscopy.~3. - Resuspension of the cells by gentle manual shaking of the vials. Once the cells are resuspended, they will be used immediately.~4. - Injection of the cell suspension with a long, fine needle (those usually used in endoscopic puncture, \<22G) at 2 points of the sphincter that will coincide with the 3 o'clock and 9 o'clock position of the hands of a clock). The injection will be superficial, trying not to go deeper than 2 mm to create a wheal in each injection visible endoscopically.~5. - Cellular remains, if any, and the vials used will be eliminated following the usual procedures used for the management of hospital surgical waste.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo implantation is carried out in the same way as the drug implantation
Study: NCT06738589

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: non-invasive ventilation
Description: Non-invasive ventilation adds positive pressure to the upper airway via a mask on the face.
Study: NCT06740539

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Catheter ablation of atrial fibrillation
Description: Catheter ablation of atrial fibrillation
Study: NCT06746883

Intervention type: DRUG
Intervention: Sulbactam-Durlobactam
Description: 1.0 g sulbactam/1.0 g durlobactam
Study: NCT06759493

Intervention type: DIAGNOSTIC_TEST
Intervention: Retinol isotope dilution technique
Description: A group of 60 school children will be recruited through a stratified sampling. To this first group of 60 school children a retinol isotope dilution (RID) test for total body store assessment will be applied. The remaining 98 school children will be recruited according to stratified sampling and divided into two groups of 49 children (females and males). To these groups of children, the modified relative dose response (MRDR) test, a qualitative measure of vitamin A status will be used to investigate the absorption of 3,4-didehydroretinyl acetate in oil.
Study: NCT05366933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin B-Complex Supplement
Description: Vitamin B-Complex Supplement containing: 5-methyltetrahydrofolate, riboflavin 5 phosphate, pyridoxal phosphate, and methylcobalamin
Study: NCT05805969

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Accommodating variable-resistance training
Description: The training was conducted twice weekly for six successive weeks under the close supervision of a licensed pediatric physical therapist in accordance with the safety performance guidelines defined by the American Academy of Pediatrics and the US National Strength and Conditioning Association.~The training protocol included maximum voluntary concentric knee flexor/extensor actions. Three sets of five to 10 repetitions of maximum-effort concentric action at angular speeds of 240, 180, and 120 degrees/second.~The training started with a 10-minute warm-up exercise and ended up with a 5-minute cool-down exercise.
Study: NCT05805969

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard physical therapy
Description: The program encompassed the standard exercises for patients with juvenile idiopathic arthritis (aerobic, weight-bearing, proprioceptive, flexibility, and strengthening exercises). The training was conducted for 45 minutes, two times a week for six successive weeks.
Study: NCT06771297

Intervention type: OTHER
Group type: OTHER
Intervention: nursing education
Description: Nursing training will be given before rhinoplasty surgery. As a result, patients' involuntary thoughts and quality of recovery will be questioned.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nursing education
Description: Nursing training will be given before rhinoplasty surgery. As a result, patients' involuntary thoughts and quality of recovery will be questioned.
Study: NCT06771804

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cricket Protein
Description: Participants are provided with muffins containing either whey or cricket protein.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cricket Protein
Description: Participants are provided with muffins containing either whey or cricket protein.
Study: NCT06770101

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral: Enhanced Friendship Bench + Safety Planning
Description: The protocol will include six sessions, starting with the development of the SP during the first session. Each of the following sessions will include SIBs and suicide risk assessments, SP check-ins and revisions, as well as FB problem-solving to address SIBs and suicide risk. SP+FB will be delivered by selection of young counselors (mixed genders, aged 20-35) who are motivated to work with young people. Counseling sessions will take place in a discrete location within the HIV clinic and be available on weekends. Each structured session lasts 30-45 minutes and conducted in the participant's local language (Chichewa). After 4 sessions of individual therapy, the counselor can refer participants not improving or with suicidal ideation to a supervisor trained in mental health to reassess and manage the case. Case management may include additional counseling or pharmacotherapy, at the discretion of the managing clinician. Participants may also receive text message support and peer-support.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Augmented usual care
Description: Care for suicidality in public facilities in Malawi includes options for basic supportive counseling by the primary provider or nurse, medication management by the primary provider, referral to the clinic's psychiatric nurse, or, for acute cases or crises, referral to the psychiatric units at tertiary care hospitals (Bwaila Hospital in Lilongwe District). Nurses and clinicians at the study sites have been specifically trained to use the Tool for Assessment of Suicide Risk for Adolescents (TASR-A) to assess ALWH considered at elevated risk for suicide. For this study, usual care will be augmented by a trained study nurse who will provide mental health evaluation, brief supportive counseling, information, education and support on SIBs, and (if indicated) facilitation of referral to the clinic's psychiatric nurse or to Bwaila Hospital.
Study: NCT06777849

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Right to Play-Plus (RTP-Plus)
Description: The comprehensive curriculum comprises of themes: Social and Emotional Development and Sexual and Reproductive Health will be delivered by school teachers who will receive training from Right to Play and Aahung. There will be 60 sessions for two years.

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: There will be no intervention given to control arm during two years of cluster randomised control trial (cRCT). However, a delayed intervention having teachers' training, will be provided to the control arm after the completion of endline for the duration of 3-4 months.
Study: NCT06778863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLSP-1025
Description: CLSP-1025 will be administered by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLSP-1025
Description: CLSP-1025 will be administered by IV infusion
Study: NCT06781749

Intervention type: DEVICE
Intervention: Hearing aid use
Description: Hearing aid use will be discussed with all eligible participants with hearing loss and will be encouraged to pursue hearing aid fitting through standard clinical indications via participants' insurance and audiologists.